TERFONYL Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Terfonyl, and when can generic versions of Terfonyl launch?
Terfonyl is a drug marketed by Bristol Myers Squibb and is included in one NDA.
The generic ingredient in TERFONYL is trisulfapyrimidines (sulfadiazine;sulfamerazine;sulfamethazine). Additional details are available on the trisulfapyrimidines (sulfadiazine;sulfamerazine;sulfamethazine) profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for TERFONYL?
- What are the global sales for TERFONYL?
- What is Average Wholesale Price for TERFONYL?
Summary for TERFONYL
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 133 |
| Patent Applications: | 5,154 |
| DailyMed Link: | TERFONYL at DailyMed |
US Patents and Regulatory Information for TERFONYL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bristol Myers Squibb | TERFONYL | trisulfapyrimidines (sulfadiazine;sulfamerazine;sulfamethazine) | SUSPENSION;ORAL | 006904-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Bristol Myers Squibb | TERFONYL | trisulfapyrimidines (sulfadiazine;sulfamerazine;sulfamethazine) | TABLET;ORAL | 006904-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
More… ↓
